Which of the following anti-HIV drug should never be given as rechallenge once history of producing allergic reaction with drug is known?
**Core Concept:** Understanding the concept of drug allergy and its implications, particularly in HIV treatment.
**Why the Correct Answer is Right:** Drug allergy refers to an adverse reaction to a substance due to an immune response. In the context of HIV treatment, rechallenging a patient with an allergenic drug can lead to a severe and potentially life-threatening reaction. Therefore, we should avoid rechallenging a patient with a known allergenic drug.
**Why Each Wrong Option is Incorrect:**
A. Zidovudine (AZT): Although AZT is an anti-HIV drug, it is not specifically mentioned as an allergenic drug. Therefore, this option is incorrect as it does not address the core concept of avoiding allergenic drugs.
B. Raltegravir: Although raltegravir is an anti-HIV drug, it is not specifically mentioned as an allergenic drug. Thus, this option is incorrect according to the core concept emphasized in the question.
C. Lamivudine: Similar to options A and B, lamivudine is an anti-HIV drug but is not specifically known as an allergenic drug. This makes it incorrect in relation to the core concept.
D. Nevirapine: Nevirapine is an anti-HIV drug and was identified as causing cutaneous reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which is an allergic reaction. This option directly addresses the core concept of avoiding allergenic drugs in rechallenge situations, making it correct.
**Clinical Pearl:**
In clinical practice, it is essential to understand the potential for drug allergic reactions when rechallenging patients with a known history of drug allergy. Always consider the possibility of a severe or fatal allergic reaction and avoid rechallenging patients with known allergenic drugs.
**Correct Answer:** Nevirapine (NVP)
---
**Why the Correct Answer is Right:** Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NRTI) used in HIV treatment. It can cause severe cutaneous reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which are allergic reactions. This information highlights the potential for severe allergic reactions when rechallenging patients with a history of drug allergy, making it crucial to avoid rechallenging patients with known allergenic drugs.
**Why Each Wrong Option is Incorrect:**
A. Zidovudine (AZT): This nucleoside reverse transcriptase inhibitor (NRTI) is not specifically known to cause severe cutaneous reactions like SJS or TEN. It is primarily used as a nucleoside reverse transcriptase inhibitor (NRTI) in HIV treatment.
B. Raltegravir: Raltegravir is a protease inhibitor (PI) used in HIV treatment. It is not known to cause severe cutaneous reactions like SJS or TEN, making it an acceptable choice for rechallenging patients with a history of drug aller